Dublin, Ireland-December 14th, 2009
ICON plc has expanded its European Central Laboratory, located in South County Business Park, Dublin. The newly-designed 41,000 sq ft (3,800m²) facility, which is three times the size of the previous laboratory, provides centralized testing and site support services to clinical investigators in over 70 countries throughout Europe, Middle East, and Africa.
The new laboratory incorporates enhanced automation which is intended to enable reductions in turn-around time for sample testing and reporting, and according to the company, has quadrupled the laboratory’s sample management and storage capacity. In addition, the larger facility has enabled the introduction of new platforms to enhance ICON’s test menu in specialized areas including microbiology, molecular diagnostics, flow cytometry, endocrinology, and RIA. New laboratories have also been created in an effort to accommodate more specialized testing services in the areas of anatomic pathology, molecular diagnostics, and multiplex assays, which will be operational in early 2010.
“Efficient sample management and reporting, and providing an extensive test menu are key fundamentals of any laboratory,” commented Peter Gray, CEO at ICON plc. “The extra capacity in our Dublin laboratory enables ICON to extend our capabilities to support clients’ demands for more sophisticated testing.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.